Equities researchers at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 0.7 %
NASDAQ TTNP opened at $4.30 on Thursday. Titan Pharmaceuticals has a 12 month low of $4.24 and a 12 month high of $14.80. The firm’s fifty day moving average price is $5.59 and its 200 day moving average price is $6.07.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- What is a SEC Filing?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Golden Cross Stocks: Pattern, Examples and Charts
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.